Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
作者:
主题词
青少年(Adolescent);中枢神经系统肿瘤(Central Nervous System Neoplasms);儿童, 学龄前(Child, Preschool);爱泼斯坦巴尔病毒感染(Epstein-Barr Virus Infections);女(雌)性(Female);HLA抗原(HLA Antigens);疱疹病毒4型, 人(Herpesvirus 4, Human);组织相容性试验(Histocompatibility Testing);人类(Humans);免疫疗法, 过继(Immunotherapy, Adoptive);婴儿(Infant);平滑肌肉瘤(Leiomyosarcoma);许可证(Licensure);肺肿瘤(Lung Neoplasms);淋巴组织增殖性疾病(Lymphoproliferative Disorders);男(雄)性(Male);中年人(Middle Aged);新西兰(New Zealand);手术后并发症(Postoperative Complications);缓解诱导(Remission Induction);肉瘤(Sarcoma);T细胞抗原受体特异性(T-Cell Antigen Receptor Specificity);T淋巴细胞, 细胞毒性(T-Lymphocytes, Cytotoxic);组织库(Tissue Banks);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.1111/bjh.13051
PMID
25066775
发布时间
2021-10-21
- 浏览57
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文